CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Anticoagulation - oral - Management
Basis for recommendation
The list of interactions discussed is based on those in the core summary of product characteristics for warfarin [MHRA, 2009b].
- Information on individual drug interactions can be found in the electronic Medicines Compendium (eMC) (http://emc.medicines.org.uk) and the British National Formulary (BNF) (www.bnf.org) [BNF 57, 2009].
- The evidence base for these interactions can be found in Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management [Baxter, 2008].
- Specific concerns about non-pharmacological products such as cranberry juice [CSM, 2004], glucosamine [CHM, 2006], St John's wort [CSM, 2000], and stopping smoking [MHRA, 2009a] have been addressed by the Medicines and Healthcare products Regulatory Agency (MHRA), formerly the Committee on Safety of Medicines (CSM).
- Concerns about selective serotonin reuptake inhibitors, tricyclic antidepressants, mirtazapine, and St John's wort, have been addressed by the NICE guideline Depression with a chronic physical health problem [NICE, 2009].
© NHS Institute for Innovation and Improvement